Bevacizumab-associated hypertension: etiology, incidence, and management.
Bevacizumab (Avastin) is a recently developed monoclonal antibody, which targets the vascular endothelial growth factor signaling pathway, and is currently used in combination with cytotoxic agents as first-line or second-line therapy for patients with metastatic colon cancer. Hypertension is a known risk factor associated with the use of bevacizumab. In this report, we describe the incidence, etiology, and management of patients with this complication.
aDepartment of Gastrointestinal and Endocrine Surgery, UT Southwestern Medical Center/VA North Texas Health Care System bDepartment of Medicine, Division of Hematology/Oncology, Dallas, Texas, USA.
Sergio
S
Huerta
Hsiao C
HC
Li